Form 4: Pediatrix CEO Sells 23,000 Shares Under 10b5-1 Plan
Insider Transaction Report
Pediatrix Medical Group CEO Mark S. Ordan reported the sale of 23,000 shares of common stock for a weighted average price of $22.41 per share.
Summary
- Mark S. Ordan, Chief Executive Officer and Director of Pediatrix Medical Group, Inc. (MD), sold 23,000 shares of the company's common stock.
- The transaction occurred on December 15, 2025.
- The shares were sold at a weighted average price of $22.41 per share, with individual sales prices ranging from $22.00 to $22.62.
- Following this transaction, Mr. Ordan beneficially owns 302,805 shares of common stock.
- The sale was executed pursuant to a Rule 10b5-1(c) plan, indicating it was a pre-arranged transaction.
- A Power of Attorney was granted by Mark S. Ordan on October 28, 2025, to Mary Ann E. Moore and Tara McManus to facilitate SEC filings on his behalf.
Sentiment
Score: 4
Explanation: The sale of shares by a CEO, even if pre-planned, can be perceived as a slight negative signal, though the presence of a 10b5-1 plan mitigates immediate concerns about insider sentiment. It's a routine disclosure for an insider transaction.
Negatives
- CEO Mark S. Ordan sold 23,000 shares of company common stock.
- Insider selling, even when pre-planned under a 10b5-1 plan, can sometimes be perceived negatively by the market as it reduces insider ownership.
Future Outlook
NA
Industry Context
This is a routine insider transaction report and does not provide specific industry context beyond the company's sector in healthcare services. It reflects an individual's stock management rather than broader industry trends.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney Grant | Mark S. Ordan granted a Power of Attorney to Mary Ann E. Moore and Tara McManus to handle SEC filings on his behalf, including Forms 3, 4, 5, 13D, 13G, and 144. | 10/28/2025 | Streamlines the process for insider reporting compliance for Mr. Ordan, ensuring timely and accurate submissions to the SEC. |
Stakeholder Impact
- Shareholders: May interpret the insider sale as a signal regarding management's view of the company's valuation, although the 10b5-1 plan suggests the sale was not based on new, non-public information.
Key Dates
| Date | Description |
|---|---|
| 10/28/2025 | Date Power of Attorney was executed by Mark S. Ordan. |
| 12/15/2025 | Date of earliest transaction (sale of common stock). |
| 12/17/2025 | Date Form 4 was signed by Attorney-in-Fact. |
Recommendation
holdThe filing reports a routine, pre-scheduled insider sale by the CEO under a Rule 10b5-1 plan. While insider selling can sometimes be viewed negatively, the pre-planned nature suggests it's not based on new, adverse information. Without additional context on the company's performance or strategic direction, this single transaction does not warrant a change from a 'hold' position.
Keywords
Pediatrix Medical Group, MD, Mark S. Ordan, Insider Sale, Form 4, CEO, Director, Stock Transaction, Rule 10b5-1, Healthcare Services
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.